SCHEMBL405614

SCHEMBL405614

[c]1cn(-c2ccccc2)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.39
KDM4E B2RXH2 3/20 0.37
ATM Q13315 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
POLB P06746 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
NR4A2 P43354 1/20 0.31
FGFR1 P11362 4/20 0.31
SRC P12931 2/20 0.31
PGR P06401 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481750 0.84 KMT2A (0.34) HTTMEN1KMT2APOLBFGFR1
SCHEMBL4014977 0.84 L3MBTL1 (0.38) HTTKDM4EATML3MBTL1MEN1
SCHEMBL6480842 0.81 CYP2A6 (0.41) HTTL3MBTL1FGFR1SMN1; SMN2ALDH1A1
SCHEMBL4275590 0.80 FGFR1 (0.50) MEN1NPC1RAB9AKMT2AFGFR1
SCHEMBL150844 0.79 FGFR1 (0.46) KDM4EL3MBTL1MEN1NPC1RAB9A
SCHEMBL408242 0.74 BIRC5 (0.38) HTTKDM4EATML3MBTL1DDB1
SCHEMBL6308233 0.72 KDM4E (0.45) HTTKDM4EDDB1CRBNMEN1
SCHEMBL16720539 0.70 AHR (0.37) KDM4EMEN1KMT2APOLBALDH1A1
SCHEMBL16719930 0.69 CYP17A1 (0.39) KDM4EPOLBCYP1A2HSD17B10
SCHEMBL193935 0.68 GPR3 (0.37) KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116903597-A Compound containing triazine and carbazole structures and organic electroluminescent device 江苏三月科技股份有限公司 2023-10-20 CN claimed
CN-111689989-B Containing SO2Polyheterocyclic compounds and uses thereof 北京燕化集联光电技术有限公司 2021-11-02 CN claimed
CN-111662298-B Compound containing multiple heterocyclic rings and application thereof in organic electroluminescent device 北京燕化集联光电技术有限公司 2021-08-10 CN claimed
CN-112521360-A Arylamine organic compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2021-03-19 CN claimed
CN-111675713-A Arylamine compound and organic light-emitting device thereof 长春海谱润斯科技有限公司 2020-09-18 CN claimed
JP-4769461-B2 2011-09-07 JP claimed
EP-1716160-B1 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-29 EP claimed
US-20100048513-A1 Novel inhibitors of chymase HAWKINS MICHAEL J 2010-02-25 US claimed
US-7648738-B2 for photopolymerization; photography, relief imaging; color filters CIBA SPECIALTY CHEMICALS CORPORATION (US) 2010-01-19 US claimed
EP-1567518-B1 OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS CIBA HOLDING INC (CH) 2009-01-14 EP claimed
US-7459444-B2 Inhibitors of chymase JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-02 US claimed
EP-1032709-B1 METHOD AND APPARATUS FOR PRESERVING HUMAN SALIVA FOR TESTING SCHNEIDER DAVID R (US) 2008-06-11 EP claimed
US-20060241259-A1 Oxime ester photoinitiators with heteroaromatic groups CIBA CORPORATION 2006-10-26 US claimed
JP-2006516246-A 2006-06-29 JP claimed
EP-1567518-A2 OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS Ciba SC Holding AG (CH) 2005-08-31 EP claimed
US-20050176769-A1 Novel inhibitors of chymase JANSSEN PHARMACEUTICA, N.V. (BE) 2005-08-11 US claimed
WO-2004050653-A2 OXIME ESTER PHOTOINITIATORS WITH HETEROAROMATIC GROUPS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-06-17 WO claimed
EP-0299972-B1 ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1992-03-04 EP claimed
EP-0299972-A1 ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. UPJOHN CO (US) 1989-01-25 EP claimed
WO-1987006132-A1 ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-10-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048513-A1 Novel inhibitors of chymase CMA1, SERPINB1, TPSAB1 HTT 4560/4885KDM4E 2832/4885ATM 2985/4885
US-20050176769-A1 Novel inhibitors of chymase CMA1, SERPINB1, TPSAB1 HTT 4560/4885KDM4E 2832/4885ATM 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.